P
Parthenon Therapeutics
Inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment
About Parthenon Therapeutics
Parthenon Therapeutics is a startup that operates in the biotechnology industry, focusing on the development of therapeutics. The company is led by Wendye, a seasoned entrepreneur with a track record of building successful companies from scratch and raising over $1 billion in public and private markets. She has been instrumental in the development of various therapeutics, including Qutenza™, Ajovy™, and others in the pipeline.
Read full description
Parthenon Therapeutics' business model revolves around the development and commercialization of therapeutics. The company collaborates with investors and other companies to raise funds, develop therapeutics, and bring them to market. Once the therapeutics are developed, they are sold to larger pharmaceutical companies or brought to market by Parthenon Therapeutics itself. The company's revenue is generated from the sale of these therapeutics.
The company's clients are primarily large pharmaceutical companies interested in acquiring new therapeutics. However, Parthenon Therapeutics also works with investors who provide the necessary funding for the development of these therapeutics.
The company's Chief Medical Officer, Dr. Joseph Paul Eder, brings over 30 years of clinical experience from leading cancer research institutions and the pharmaceutical industry. His expertise further strengthens the company's ability to develop effective therapeutics.
In summary, Parthenon Therapeutics is a biotechnology startup that develops therapeutics and brings them to market, either by selling them to larger pharmaceutical companies or commercializing them itself. The company is led by experienced professionals and operates in a high-growth market.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Cambridge, United States
- Employees
- 24
- Open positions
- None listed
- Dealroom signal
- 61.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Parthenon Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Nov 2021 | $65M | $260M | Section 32 · KdT Ventures · Park West Asset Management · Breakout Ventures | — |
Growth signals
Latest recorded traffic for Parthenon Therapeutics is 1.5K monthly website visits, down 28.6% over the last three months. Parthenon Therapeutics's team declined 22.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Northpond Ventures- TVTaiho Ventures
Section 32
KdT Ventures
Park West Asset Management
Breakout Ventures
Alexandria Equities- PVPfizer Ventures
- CVCreacion Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Parthenon Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Parthenon Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.